Trial Profile
A phase Ia, open-label, dose-escalation study of CGX-1160 in neuropathic pain following spinal cord injury
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2016
Price :
$35
*
At a glance
- Drugs Contulakin G (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man
- 26 Aug 2016 New trial record
- 01 Jul 2016 Results published in the Clinical Pharmacology in Drug Development